10-K: Achieve Life Sciences Files 10-K, Provides Update on Cytisinicline Development

Achieve Life Sciences' 10-K filing details the company's financial status, clinical trial progress, and regulatory pathway for its lead product candidate, cytisinicline.

Summary

• Achieve Life Sciences is a clinical-stage pharmaceutical company focused on developing cytisinicline for smoking cessation and nicotine addiction.
• The company has completed Phase 3 trials (ORCA-2 and ORCA-3) for cytisinicline, showing positive results for both 6 and 12-week treatment durations compared to placebo.
• A new open-label trial (ORCA-OL) is planned to assess long-term safety, with data expected to support an NDA submission in the first half of 2025.
• The company has an exclusive license and supply agreement with Sopharma for cytisinicline outside of certain European territories.
• Achieve is also exploring cytisinicline for e-cigarette cessation, with positive Phase 2 results (ORCA-V1) and plans for a potential Phase 3 program.
• The company reported a net loss of $29.8 million for the year ended December 31, 2023, and has an accumulated deficit of $165.8 million.
• As of December 31, 2023, Achieve had $15.5 million in cash and cash equivalents and a negative working capital balance of $3.8 million.
• The company has a convertible term loan of $16.6 million, which matures on December 22, 2024, but may accelerate to August 1, 2024, if certain NDA filing conditions are not met.
• Achieve has raised additional capital through a registered direct offering in February 2024, generating net proceeds of approximately $56.2 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting successful clinical trial results and a clear regulatory path. However, the company's financial losses, debt, and reliance on a single supplier introduce some risk, preventing a higher sentiment score.

Positives

• Cytisinicline has shown robust efficacy in Phase 3 trials for smoking cessation, with both 6 and 12-week treatments demonstrating significant benefits.
• The ORCA-V1 trial indicates cytisinicline's potential as a treatment for e-cigarette cessation.
• The company has secured additional funding through a registered direct offering, strengthening its financial position.
• Achieve has an exclusive license and supply agreement with Sopharma, ensuring a supply of cytisinicline.
• The company has reached an agreement with the FDA regarding the long-term safety data requirements for NDA submission.

Negatives

• The company has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future.
• Achieve is dependent on a single supplier, Sopharma, for the manufacture and supply of cytisinicline.
• The company has a convertible term loan of $16.6 million, which matures on December 22, 2024, but may accelerate to August 1, 2024, if certain NDA filing conditions are not met.
• The company has a negative working capital balance of $3.8 million as of December 31, 2023.

Risks

• The company's success is heavily reliant on the successful development and commercialization of cytisinicline.
• There is no guarantee that the FDA will approve cytisinicline, and additional clinical or non-clinical studies may be required.
• The company is dependent on a single supplier for cytisinicline, and any disruption in supply could negatively impact operations.
• The company faces substantial competition in the smoking cessation market.
• The company has incurred substantial debt, which could impair its flexibility and access to capital.
• The company's cash and cash equivalents could be adversely affected if the financial institutions in which it holds its cash and cash equivalents fail.

Future Outlook

Achieve plans to submit an NDA for cytisinicline in the first half of 2025, supported by data from the ORCA-OL trial. The company also intends to pursue a potential Phase 3 program for e-cigarette cessation.

Management Comments

• The company believes cytisinicline represents a unique opportunity to significantly impact global health by addressing the considerable unmet need among millions of smokers and e-cigarettes users.
• The company believes cytisinicline is differentiated from existing smoking cessation treatments given its combination of robust efficacy, minimal frequency of side effects and optional shorter course of therapy.

Industry Context

The document highlights the significant unmet need in the smoking cessation market, with over 28 million adult smokers in the US and a growing number of e-cigarette users. The company positions cytisinicline as a potential first-in-class prescription treatment for both smoking and vaping cessation, addressing the limitations of existing prescription and over-the-counter options.

Comparison to Industry Standards

• The document mentions that current prescription treatments like varenicline (Chantix) and bupropion (Zyban) have significant side effects and require longer treatment periods (3 months and 7-12 weeks respectively), while cytisinicline has shown robust efficacy with minimal side effects and optional shorter treatment durations in Phase 3 trials.
• The document also notes that over-the-counter nicotine replacement therapies (NRTs) are generally less effective than prescription drugs, positioning cytisinicline as a potentially superior option.
• The company cites a Cochrane Group review that demonstrated varenicline is more effective than NRTs, further highlighting the need for more effective prescription treatments.
• The document references a DelveInsights report estimating the global market for prescription smoking cessation therapies to reach $5.6 billion by 2030, indicating the significant market opportunity for cytisinicline.

Related Party Transactions

• The company has a license and supply agreement with Sopharma, a related party.
• The company has a Share Purchase Agreement with Sopharma AD to acquire 75% of Extab Corporation.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial results will directly impact shareholder value.
• Employees: The company's ability to attract and retain talent is crucial for its success.
• Customers: The company aims to provide a safe and effective treatment for smoking and nicotine addiction.
• Suppliers: The company relies on Sopharma for the supply of cytisinicline.
• Creditors: The company has a convertible term loan, which could impact its financial stability.

Next Steps

• Initiate the open-label ORCA-OL trial in the second quarter of 2024.
• Submit an NDA for cytisinicline in the first half of 2025.
• Request an end-of-Phase 2 meeting with the FDA during 2024 to discuss a potential Phase 3 program for e-cigarette cessation.

Key Dates

Keywords

cytisinicline, smoking cessation, nicotine addiction, e-cigarette cessation, Phase 3 trials, NDA, Sopharma, ORCA-2, ORCA-3, ORCA-V1, ORCA-OL, FDA, clinical trials, regulatory approval, biopharmaceutical